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AbstraCf 
THE EFFECTS OF LEVAMISOLE, CORYNEBACTERIUM PARVUM, 
AND UNBLOCKED LYMPHOCYTES ON MICE INJECTED WITH 
HERPES VIRUS TYPE 2-TRANSFORMED CELLS 
by Linda Martin Kelln 
The association between herpes simplex virus type-2 and carcinoma 
of the cervix is becoming increasingly strong (Rawls, et�-, 1976; 
Rapp and Duff, 1974; Hollingshead, et tl-, 1973). This study demon­
strates the ability of certain known immunostimulators to beneficially· 
alter the immune status of mice injected with HSV-2 transformed cells. 
Balb/c mice were randomly divided into 6 groups. Group 1 mice 
were used as negative controls and received no tumor cell injection. 
All other groups received subcutaneous injections of 1 x 106 cells/
mouse. Tumor therapy by means of irrmunostimulation was started for 
each group of mice 1 day after the initial tumor cell injection and 
proceeded on a weekly basis for a total of 7 weeks before sacrifice. 
Group 1 non-injected mice received no tumor therapy. Group 2 
mice were used as positive controls and also received no immuno� 
stimulatory therapy. Mice in group 3 received 200 µgm of levamisole, 
a non-specific immune stimulator. Group 4 mice were given 300 µgm 
of heat and formalin killed Corynebacterium parvum which is known to 
non�specifically stimulate macrophage populations. Mice in group 5 
received unblocked lymphocytes at a concentration of 4 x 106 cells/
mouse. Group 6 mice received a combination therapy of levamisole, 
C. parvum and unblocked lymphocytes. 
Weekly measurements of tumor volume were made using vernier 
calipers. At the time of sacrifice specific cytotoxicity tests 
were performed. These included the antibody-dependent cell-mediated 
cytotoxicity (ADCC) test, the blocking factor (BF) assay and the 
cytolytic T-lymphocyte (CTL) test. The lymphocyte transformation test 
using phytohemagglutinin, a T-cell mitogen, was also performed at 
the time of sacrifice, using mouse spleen cells. 
Levamisole was unable to significantly stimulate the immune 
status of group 3 animals and showed no apparent benefit in reducing 
tumor volume. Unblocked lymphocytes administered to group 5 mice 
may have had some stimulatory effect upon the immune status of the 
tumor mice, but it was not significant. Tumor volume was the greatest 
for group 5 mice and significantly higher than for those mice treated 
only with C. parvum (group 4) or the combination therapy (group 6). 
ADCC and BF cytotoxicity results did tend to indicate that C. 
parvum alone and in combination with levamisole and unblocked lymph-
octyes was able to stimulate the immune responses, of group 4 and 6 
animals. Tumor volumes were the lowest for these 2 groups. Combin-
ation group 6 mice had the lowest tumor incidence also. 
It was concluded from this study that the combination of lev-
amisole, C. parvum and unblocked lymphocytes did have an enhancing 
effect upon the immune status of tumor hosts, which may actually aid 
in lowering tumor incidence and progression. 
2 
LOMA LINDA UNIVERSITY 
Graduate School 
THE EFFECTS OF LEVAMISOLE, CORYNEBACTERIUM PARVUM, 
AND UNBLOCKED LYMPHOCYTES ON MICE INJECTED WITH 
HERPES VIRUS TYPE 2-TRANSFORMED CELLS 
by . 
Linda Martin Kelln 
A.Thesis.in Partial Fulfillment of the
Requirements for the Degree Master of 
Science in the Field of Microbiology 
August 1981 
Each person whose signature appears below certifies that this 
thesis in his/her opinion is adequate, in scope and quality, as 
a thesis for the degree of Master of Science. 




-Pi  Rob r L. Nutter, Proftssor of Microbiology 
Robert W. Teel, Associate Professor 
of Physiology 
ACKNOWLEGMENTS 
I would like to express my deep felt gratitude to the following 
people who helped make this project possible: 
Wayne Kelln, my husband, for his programming and computing assistance 
along with his unfailing patience and support. 
Dr. James D. Kettering, my major professor, for his understanding and 
flexible attitude, his ever encouraging words, and his interest 
in making this project a success. 
Dr. Daila S. Gridley, an indispensible member of this project, for her 
overall expertise in the area of study, her knowledge of technical 
proceedures and equipment, and her encouragement. 
Drs. R. L. Nutter and R. W. Teel, members of my committee, for their 
helpful suggestions and guidence. 
Melba Andress and Ray Aprecio, for their superb technical assistance. 
Laveta Martin, my mother, for her swift and accurate typing skills. 
The Microbiology Department Staff, for their confidence and encourage- 
ment through what might otherwise have been a very trying two and 
a half years. 
TABLE OF CONTENTS 
Page 
SIGNATURE PAGE  	ii 
ACKNOWLEDGEMENTS 	  iii 
LIST OF TABLES  vii 
LIST OF FIGURES  
INTRODUCTION . . 	 1 
Transforming Potential 
Immune Response to Tumor Challenge 
Methods for Measuring Cell-Mediated 
Immunotherapy in Tumor Hosts 
 
 
Levamisole . 	• • .............. • • 	7 
Corynebacterium parvum  	9 
Unblocked Lymphocytes  	11 
Combination Therapy  	12 
13 
Mice  	 13 
H238 Tumor Cells  	13 
Media  	13 
Buffers  	14 
Radioactive Compounds  	14 
Tumor Cell Injection  	14 
Treatment of Control and Therapy Mice  	15 
Labeling H238 Target Cells  	17 
Effector Cells  	18 








MATERIALS AND METHODS 
iv 
TABLE OF CONTENTS (continued) 
Page 
Target Cell Incubation 	CTT  	18 
1. Antibody-Dependent Cell Mediated Cytotoxicity 
(ADCC) 	  18 
2. Blocking Factor (BF)  	19 
3. Cytolytic T-Lymphocytes (CTL)  	19 
4. Non-Specific Lysis (NSL)  	20 
Cytotoxicity Assays  	20 
NSL Calculations  	21 
ADCC Calculations  	21 
BF Calculations  	22 
CTL Calculations  	22 
Lymphocyte Transformation Test - LTT  	22 
Stimulation Index - (S  I )  	23 
Relative Spleen Weight - (R S W )  	23 
Tumor Volume  	24 
Statistical Analysis  	24 
RESULTS  	25 
Cytotoxicity Assay Results  	25 
1. Antibody-Dependent Cell-Mediated Cytotoxicity  	25 
2. Blocking Factor  	25 
3. Direct Cytolysis - (Cytolytic T-Lymphocytes)  	30 
Lymphocyte Transformation Test Results .. 	. . 	30 
1. Stimulation Index (S.I.) - Spleen Cells  	30 
TABLE OF CONTENTS (continued) 
Page 
Relative Spleen Weight (R.S.W.) 	 34 
• Progressive Tumor Measurements  	35 
1. Tumor Volume  	35 
2. Tumor Incidence  	39 
DISCUSSION 	 42 
CONCLUSIONS • • 	• OOOOOOOOOOOO • • • O 	O • • 	51 
LITERATURE CITED  	53 
vi 
LIST OF TABLES 
Table 	 Page 
	
I 	TREATMENT SCHEDULE AND TEST SYSTEMS  	16 
II 	CYTOTOXICITY RESULTS  	26 
III 	P VALUES OBTAINED FOR TUMOR VOLUME, RELATIVE 
SPLEEN WEIGHT, STIMULATION INDEX, BLOCKING 
FACTOR, CYTOLYTIC T-LYMPHOCYTES AND ANTIBODY- 
DEPENDENT CELL-MEDIATED CYTOTOXICITY RESULTS . .  	28 
IV 	STIMULATION INDEX RESULTS  	32 
V 	RELATIVE SPLEEN WEIGHTS . ....... . 	36 
VI 	INCIDENCE OF PROGRESSOR, REGRESSOR AND NO 
VISIBLE TUMOR MICE  	40 
vii 
LIST OF FIGURES 
Figure Page 
1 LEVAMISOLE STRUCTURE 8 
2 ANTIBODY-DEPENDENT CELL-MEDIATED 
CYTOTOXICITY RESULTS 	  27 
3 BLOCKING FACTOR RESULTS  29 
4 CYTOLYTIC T-LYMPHOCYTES 	  31 
5 LYMPHOCYTE TRANSFORMATION TEST RESULTS . 33 
6 RELATIVE SPLEEN WEIGHTS 	  37 
7 TUMOR VOLUME IN CUBIC MILLIMETERS 	 38 
8 INCIDENCE OF PROGRESSOR, REGRESSOR AND NO 
VISIBLE TUMOR MICE 41 
viii 
Introduction  
It has long been established that viruses play a major role in 
the development of certain animal tumors (Jawetz, et al., 1980; 
Friend, 1965, 1959; Gross, 1951). However, evidence as to the function 
of viruses in human neoplasia has been much slower in evolving 
(Hellstrom and Hellstrom, 1969). 
Major associations have been suggested between carcinoma of the 
cervix and herpes simplex virus (HSV) (Rawls, et al., 1976; Nahmias, 
et al., 1976; Hollinshead, et al., 1973, 1976; Aurelian, 1973; 
Aurelian, et al., 1973; Frenkel, et al., 1972). Serological evidence 
is strong in supporting such a relationship. However, this is not 
absolute proof that HSV is the major cause of cervical cancer. 
As early as 1970, Tarro and Sabin isolated nonvirion antigens 
specific for HSV 1 and HSV 2. Using this information, specific anti-
bodies for HSV 2 were found in association with cervical carcinoma 
patients (Rawls, et al., 1976; Hollinshead, et al., 1973; Aurelian, 
1973; Aurelian, et al., 1973). These antibodies are type specific, 
unlike the common herpes neutralizing antibodies. Specific tumor-
associated antigens are responsible for type specific antibodies 
and have been clearly associated with exfoliating cervical carcinoma 
cells (Rapp and Duff, 1974). 
Human cervical tumor cells have been found to contain certain 
DNA sequences corresponding to portions of the HSV 2 genome (Frenkel, 
et al., 1972; Roizman and Frenkel, 1973). Viral herpes DNA, though 
in fragments or inactivated, may be potentially carcinogenic (Wise, 
et al., 1977; Hilleman, 1976; Graham, et al., 1973). This is one 
reason the work towards an effective herpes vaccine has been difficult. 
Transforming Potential of Herpes Simplex Virus  
Many investigators have shown that inactivated herpes simplex 
viruses are capable of transforming hamster, mouse and human embryonic 
fibroblasts into potentially malignant cell lines (Duff and Rapp, 1971, 
1973; Rapp and Duff, 1974; Munyon, et al., 1972; Boyd and Orme, 1975; 
Boyd, 1976; Kucera and Gusdon, 1976). Evidence for the HSV transforming 
potential has been collected. No actual virus particles have been 
recovered from the transformed cells, but virus-like particles have 
been found in the nuclei of some of them (Duff and Rapp, 1971). Boyd, 
et al., (1975), discovered specific HSV 2 antigens in transformed 238 
mouse fibroblast cells as well as specific antibodies to these antigens 
using the indirect immunofluorescence technique. 
Tumorgenicity of such transformed cell lines is well documented. 
Duff and Rapp (1971, 1973) were able to transform hamster fibroblasts 
using either HSV 1 or HSV 2. All of these cell lines, however, did 
not produce tumors when injected into syngeneic animals. Boyd and 
Orme (1975) used HSV 2 (Savage strain) to transform 238 mouse fibro-
blasts (Balb/C mice) into a malignant cell line (H238 cells). The 
transformed H238 cells produced tumors with 100% incidence when injected 
at 1 x 10
6 
cells/mouse (Boyd and Orme, 1975). 
Immune Responses to Tumor Challenge .  
Through the years the theory of immune surveillance, associated 
primarily with infections, has been widely accepted (Burnet, 1959, 
1961). More recently it has been found that primary and secondary 
immunodeficiencies can also lead to higher incidence of malignancy 
(Good, 1972). Some investigators, however, have challenged this 
concept and put forth other potential explanations for the immune 
system's relationship to tumor development (Prehn and Main, 1957; 
Schwartz, 1972, 1975). Surveillance mechanisms would eliminate tumor 
cells as they arose. Much evidence instead supports the idea of 
immunostimulation or immunoregulation induced by the presence of 
tumor-associated antigens (Schwartz, 1972, 1975; Kirchner, et al, 1974). 
There is, however, a well established relationship between immuno-
competence and prognosis in progressive human cancer (Hersh, et al., 
1976; Miller, 1968). Some patients with cancer have been shown to 
have deficiencies in their immune system. These deficiencies may 
make it very hard for the immune system to effectively destroy tumor 
cells (Hersh, et al., 1970). 
There is much evidence that T-lymphocytes and their by-products 
play a major role in tumor immunology (Bansal, 1978; Tursi, et al., 
1968). Lymphocytes directly cytolytic for target tumor cells have been 
found to be of thymic origin (Plata, et al., 1976). Tumor antigens are 
apparently able to activate anti-tumor responses in T-cells (Hellstrom 
and Hellstrom, 1969). HSV tumor-associated antigens are often found 
as antecedents in patients with squamous carcinoma who have suppressed 
cell mediated immune (CMI) responses (Hollinshead, et al., 1976). 
B-cells, the antibody-producing lymphocytes, have not been found 
to play as obvious a role in tumor immunology as T-cells. Mechanisms 
have been found however, which indicate that they appear to be an 
integral part of the defense against tumors (Nahmias, et al., 1976; 
Germain, 1979). Serum globulins (antibodies) with the aid of null (K) 
cells are able to lyse HSV infected cells as well as tumor target 
cells (Pfizenmaier, et al., 1977; Nahmias, et al., 1976; Ragen-Zisman 
and Bloom, 1974; Germain, 1979). Serum blocking factors, which are• 
thought to be antibodies and/or antibody-antigen complexes, have been 
shown to decrease the ability of effector T-cells to destroy target 
tumor cells (Nowotny, et al., 1976; Ran, et al., 1976; Baldwin, et al., 
1972; Hellstr6m, et al., 1971; Hellstr6m, et al, 1970). 
Macrophages have the ability to phagocytize and degrade tumor 
cells. It is thought that the presence of a large number of macro-
phages at the tumor site may play a major role in preventing or slowing 
metastatic spread (Alexander, 1976; Eccles and Alexander, 1974; Evans, 
1972). T-lymphocytes and their products may 'arm' otherwise normal 
macrophages, and thus activate them for attack against specific tumor 
cells (Evans and Alexander, 1972a, 1972b; Evans, et al., 1972). It 
has also been suggested that cancer patients having good monocyte 
(macrophage) chemotactic responses (MCR) possess more effective cyto-
lytic T-cells. In fact, a high MCR may be an indicator of effective 
host response to disease in general (Boetcher and Leonard, 1974). If 
tumor cells, or effector cells responding to tumors, are able to attract 
macrophages to the tumor site, other factors must be considered. 
Evidence shows that tumors somehow interfere with peripheral blood 
monocytes migrating to locations of inflammation. Therefore, certain 
states of anergy in cancer patients may be partially due to macrophage 
cells which are unable to fulfill their role in immune recognition 
(Eccles and Alexander, 1974b). 
Certain lymphocyte-like cells of unknown lineage have been 
designated natural killer (NK) cells. These cells are present in the 
normal individual and are able to lyse tumor cells by direct contact, 
although the mechanism by which this takes place is not known (Germain, 
1979). 
Methods for Measuring Cell-Mediated Immunity  
The spleen houses the largest collection of reticuloendothelial 
cells in the body which function in removing foreign material. During 
the growth of a tumor, the spleen is often found to enlarge (Nutter, 
et al., 1980; Rowland, et al., 1973). The proportions of T- and 6-
lymphocytes as well as phagocytic macrophages becomes markedly altered 
with respect to those found in normal spleens. The T-cell population 
is usually between 5 and 10 percent lower than in control groups, and 
the proportions of macrophages drestically increases (Kirchner, et al., 
1974; Visakorphi, 1973). 
A commonly used method of measuring lymphocyte response in vitro  
6 
is the lymphocyte transformation test (LTT). Phytohemagglutinin (PHA), 
is T-cell mitogen, is a glycoprotein extracted from the kidney bean 
(Fisher and Mueller, 1968; Nowell, 1960). Unimpaired T-cells are 
stimulated by PHA to become metabolically more active and form large 
blast-like cells with high mitotic indices (Greaves, et al., 1974; 
Oppenheim and Perry, 1965). It is known, however, that lymphocytes 
collected from tumor-bearing hosts are generally less stimulated by 
PHA than are normal cells. The reactivity of such cells is therefore 
an important measurement of the tumor hosts' immune status (Gillette 
and Boone, 1975; Sample, et al., 1971; Hersh and Oppenheim, 1968; 
Tursi, et al., 1968). 
In vitro cytotoxicity tests (CTT) are more specific measures of 
anti-tumor activity and, therefore, provide more information with 
respect to the ability of the host to combat the tumor (Trejosiewicz, 
et al., 1978). Serum blocking factors as well as antibody dependent 
and direct T-cell cytotoxicity can be measured (Germain, 1979; 
Trejdosiewicz, et al., 1978). The ability of effector spleen cells 
to destroy target tumor cells provides valuable information regarding 
the immune status of the tumor host (Lausch, et al., 1975; Hellstrom 
and Hellstrom, 1974; Baldwin, et al., 1972; Ran, et al., 1976). 
Immunotherapy in Tumor Hosts  
That status of the immune system of a tumor host plays a role in 
determining whether regression or progression of the neoplastic state 
will occur. It is thought that certain types of treatment using 
immunopotentiators are of benefit to some cancer patients (Morton, 
1978; Sjorgren, 1977). The combination of chemotherapy and immuno-
stimulation has been shown to be very effective in treating certain 
malignancies in animal models (Bansal and Bansal, 1978; Bansal, et al., 
1978; Fisher, et al., 1975; Pearson, 1972; Currie and Bagshawe, 1970). 
Levami sole  
At one time levamisole was used only as an antihelminthic drug 
(Goldstein, 1978; Lancet, 1975). It has been reported that 
chemoimmunostimulation using levamisole has restored CMI responses to 
normal levels in patients having rheumatoid arthritis, bronchoaenic 
carcinoma, and Hodgkins disease (Huskisson, et al., 1976; Study Group 
for Bronchogenic Carcinoma, 1975; Levo, et al., 1975). Delayed skin 
hypersensitivity reactions have been shown to convert from negative 
to positive after treatment with levamisole (Verhaegen, 1973). Exper-
imentation has shown that levamisole restores host defenses only in 
immunodeficient subjects. Little evidence suggests that this chemical 
is able to stimulate a normally functioning immune system (Brulet-
Rosset, et al., 1978; Goldstein, 1978; Amery, 1976). The mode of 
action of levamisole on the immune system is not fully understood. It 
is known that its chemical structure is similar to that of a polypeptide 
hormone secreted by the thymus which aids the differentiation of 
precursor cells into T-lymphocytes (Basch, et al., 1974; Goldstein, 1974; 
Twomey, 1974; Komuro, 1973; Goldstein, 1970). A diagram of levamisole's 
structure is shown in Figure 1. 
CL 
FIGURE 1! 	LEVAM I SOLE 
- 2, 3, 5, 6 - tetrahydro - - phenyl-imidazo 
b thiazole hydrochloride 
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Sadowski (1975), showed that levamisole was effective in limiting 
metastasis due to HSV 1-transformed cells in hamster models. The deve-
lopment of tumors induced by 1,2-dimethylhydrazine were also inhibited 
in rats by the injection of levamisole in combination with unblocked 
lymphocytes (Bansal and Bansal, 1978). 
While the potential benefit of levamisole as an immunostimulator 
appears great, it seems that these benefits are does related. Exces-
sive amounts of the drug can be immunosuppressive rather than immuno-
stimulatory. Tumor enhancement has been noted in a number of experi-
ments (Focan, 1979; Sampson, 1978; Sampson, et al., 1977). 
Granulocytosis, skin rash, and febrile illness due to excessive 
levamisole therapy have also been reported (Focan, 1979; Symoens, 
et al., 1978). 
Corynebacterium parvum  
The bacillus Calmette-Guerin (BCG) has been shown to be effective 
in providing some protection to experimental animals inoculated with 
syngeneic tumor cells (Weiss, et al., 1961; Old, et al., 1960). 
However, this organism does have to be administered as a live pre-
paration which has led to certain adverse side effects. It also 
must be administered directly into the tumor site and preferably at 
the time of tumor cell inoculation (Zbar, et al., 1974; Zbar, et al., 
1970). Although the practicality of this organism in treating human 
cancer is questionable, it has led to studies involving the bacterium 
Corynebacterium parvum. 
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C. Parvum is effective in protecting against certain common 
becterial infections, such as infection due to S. aureus (Adlam, et al., 
1972). Administered in a heat and formalin killed suspension, it has 
been shown to non-specifically enhance the immune system of tumor-
bearing hosts. Activation of phagocytic macrophages seems to be the 
primary immunostimulatory response to this bacterium (Ghaffer, et 
al., 1975; Ghaffer, et al., 1974; Wolmack, 1974; Keller, 1973). 
In animal models C. parvum alone has successfully reduced death 
rates due to tumor and/or increased longevity (Fisher, et al., 1975; 
Halpren, et al., 1966; Woodruff, 1966). Israeli (1975, 1976) has 
shown that in cancer patients, either regression or slowing of tumor 
growth can be accomplished using C. parvum treatments. Others report 
that the responses to C. parvum treatments may be varied. In 1966, 
Woodruff reported that tumor development was delayed by administration 
of C. parvum, but growth progressed as quickly as in those without 
treatment once the tumors did develop. Fisher, et al., (1970) reported 
on the other hand that there was a reduction in tumor growth rate 
rather than a delay in tumor appearance. In vitro, the cytotoxicity 
of lymph node cells from tumor-bearing hosts increased with the use 
of C. parvum (Fisher, et al., 1974). Because of these and other 
experiments, specific tumor vaccines using killed tumor cells and 
C. parvum have been employed in reducing tumor progression in mice. 
The results showed that the tumor size decreased and life expectancy 
increased overall (Scott, 1975). In these experiments, however, C. 
11 
parvum without the killed tumor cells provided no positive results. 
C. parvum, unlike some immunostimulators, rarely produces any 
observable side effects tn humans (Likhite, et al., 1974). Because of 
this it may prove to be a valuable tool in the treatment of cancer 
patients. Although it is unlikely that C. parvum would significantly 
influence advanced malignancies, if used at the onset of disease or 
at the time of excisional surgery it is possible that the host's 
immune system would be enhanced to such an extent as to successfully 
combat the tumor cells (Fisher, et al., 1970). 
Unblocked T-Lymphodytes 
Certain blocking factors may limit the cytotoxic effect of T-
lymphocytes upon tumor cells both in vivo and in vitro. It has been 
shown that thoracic duct lymphocytes transferred between HL-A compatible 
siblings increase the immune response of the recipient against tumor 
progression (Yonemoto, 1976). Other experiments use the lymphocytes 
from the tumor-bearing animal (Doyle, 1974). These lymphocytes are 
washed and returned to the same host animal. It has been suggested 
that such a washing may activate or unblock the T-cells, thereby 
increasing their effectiveness against tumor cells once injected 
back into the host. Such an increase in cytotoxicity has been shown 
in vitro (Doyle, 1974). Unblocking lymphocytes with the use of proteo-
1y-tic enzymes has also been successful, thereby degrading the blocking 
factor inside the host. Patients in an anergic state have developed 
increased delayed skin hypersensitivity reactions after the unblocking 
of their T-cells (Thornes, 1974). 
Combination therapy 
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Combination therapy studies have been performed in the past using 
C. parvum and chemotherapy (Israeli, 1976; Pearson, 1972; Currie and
Bagshawe, 1970), levamisole and BCG (Bruley-Rasset, et tl·, 1978), and 
levamisole in c'ombination with unblocked lymphocytes (Bansal and 
Bansal, 1978). However, it has been demonstrated by Bansal, et tl·, 
(1978) that the combination of levamisole, -f. parvum, and unblocked 
lymphocytes given in several successive doses effectively inhibits 
progressive tumor growth in rats with 1,2-dimethylhydrazine induced 
tumors. 
MATERIALS AND METHODS 
Mice  
Five week old female Balb/c mice were obtained from the Jackson 
Laboratory (Bar Harbor, Maine). They were separated into groups, 
marked and housed eight to a cage for seven weeks before the project 
began. The.mice were fed Purina Lab Chow ad libitum and given tap 
water through the experiment. 
H238 Tumor Cells  
Originally a Balb/c embryonic fibroblast cell line (238) was 
transformed by UV - inactivated herpes simplex virus type 2 (Savage 
strain) into a malignant tumor cell line (H238). Our lab obtained 
the H238 cell line from Dr. Ann Boyd, National Cancer Institute, 
Frederick, Maryland. 
Media  
H238 cells were grown in Dulbecco's Modified Eagle Medium (Grand 
Island Biological Company, Grand Island, New York). Roswell Park 
Memorial Institute (RPMI) - 1640 medium (Grand Island Biological 
Company, Grand Island, New York) was used in any procedure involving 
lymphocytes. Both were supplemented with 10% fetal calf serum (Reheis 
Chemical Company, Phoenix, Arizona), 100 units penicillin (Pfizer, Inc., 
New York, New York), 100 pg/mt streptomycin (Eli Lilly and Company, 
Indianapolis, Indiana), 50 pg/mt tetracyline (Lederle Laboratories, 
Pearl River, New York), 100 pg/mt fungizone (E.R. Squibb and Sons, 
13 
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Inc., Princeton, New Jersey). 
All media were prepared in double distilled water. 
Buffers  
Tris buffered saline (TBS) was used in all washing procedures 
throughout the experiment. The formula for TBS is as follows: 0.14 M 
NaCl, 5.1 mM KC1, 0.38 mM Na2HPO4 • 7H20, 0.56 mM Dextrose (anhydrous), 
0.025 M Tris-(hydroxymethyl) aminomethane (Schwartz/Mann), 0.018 M 
conc. HC1, 0.49 mM MgC1 2 • 6H20 and 0.9 mM CaC1 2. 
ACK (ammonium chloride potassium) lysing buffer was used to lyse 
unwanted red blood cells. The formula for ACK lysing buffer is as 
follows: 0.01 M KHCO3, 0.16 M NH4C1 and 0.1 mM Na2EDTA. 
Double distilled water waS used to prepare all buffers. 
Radioactive Compounds  
125 I-iododeoxyuridine (
125
IUdR 	Amersham, England) was used as 
the radioisotope to label the DNA in the cytotoxic assay procedures. 
Tritiated thymidine (3H-Thymidine, New England Nuclear, Boston, 
Mass.) was used as the radioisotope to label the DNA in the lymphocyte 
transformation tests. 
Tumor Cell Injection  
H238 cells were harvested by trypsinization, suspended and 
washed three times in TBS to remove any complete Dulbecco's medium. 
The cells were counted in a hemacytometer. The cell suspension was 
adjusted to a concentration of 3.3 x 106 cells/m5. A tuberculin 
syringe (Sherwood Medical Industries Inc., Deland, Florida) was used 
15 
to make a 0.3 mk subcutaneous (s.c.) injection of the cell suspension 
into the lateral portion of the right hind leg, delivering 1 x 106  
cells/mouse. 
Treatment of Control and Therapy Mice  
Twenty-four mice were originally used for each of the six experi-
imental groups presented in Table I. 
Negative controls (group I) were not injected with H238 tumor 
cells and received no anti-tumor therapy. Positive controls (group 2) 
were injected s.c. with H238 tumor cells but received only saline in 
lieu of anti-tumor therapy. Mice in groups 3, 4, 5 and 6 were all 
injected s.c. with H238 tumor cells at a concentration of 1 x 10
6 
cells/mouse with immunostimulatory therapy beginning the following 
day and at weekly intervals thereafter. 
Two hundred micrograms (pg) of levamisole (Janssen Pharmaceutical, 
New Brunswick, New Jersey) was administered intraperitoneally (i.p.) 
to all group 3 mice. Three hundred pg of inactivated Corynebacterium  
parvum (Burroughs Wellcome, North Carolina) was administered i.p. 
into group 5 mice at a concentration of 4 x 10
6 
cells/mouse. 
These cells were obtained from a female •Balb/c mouse with a progressive 
H238 tumor twenty-four hours prior to the scheduled therapy. The 
mouse was euthanized by CO2 and the spleen was removed. A single-cell 
suspension was obtained by teasing the spleen with 2 wooden applicator 
sticks. ACK lysing buffer was added for 4 minutes at 4
o 
C to remove 
red blood cells from the spleen cell suspension. The remaining cells 
TABLE I, 	TREATMENT SCHEDULE AND TEST SYSTEMS 
INITIAL 
INJECTION TRT. #1 	TRT. #2 	TRT. #3 	TRT. #4 	TRT. #5 	TRT. #6 	TRT. #7 	SACRIFICE 
PANEL #1 DEC. 	15 DEC. 	16 DEC. 23 DEC. 30 JAN. 	6 JAN. 13 JAN. 20 JAN. 	27 FEB. 	3 
PANEL #2 DEC. 	22 DEC. 	23 DEC. 	30 JAN. 	6 JAN. 	13 JAN. 20 JAN. 27 FEB. 	3 FEB. 	10 
PANEL #3 DEC. 	29 DEC. 30 JAN. 	6 JAN. 	13 JAN. 20 JAN. 	27 FEB. 	3 FEB. 	10 FEB. 	17 
PANEL #4 JAN. 	5 JAN. 	6. JAN. 	13 JAN, 20 JAN. 27 FEB. 	3 FEB. 	10 FEB. 	17 FEB, 	24 
PANEL #5 JAN. 	12 JAN. 	13 JAN. 	20 JAN. 	27 FEB. 	3 FEB. 	10 FEB. 17 FEB.24 MAR, 3 
PANEL #6 JAN. 19 JAN. 	20 JAN. 	27 FEB. 	3 FEB. 	10 FEB. 	17 FEB. 24 MAR. 3 MAR. 10 
TEST SYSTEMS 
GROUP 1 - NON-INJECTED MICE ( NEGATIVE CONTROLS ) 
GROUP 2 - INJECTED MICE ( 1-1238 CELLS - 1)(106 CELLS/MOUSE ), NO TREATMENT ( POSITIVE CONTROLS ) 
GROUP 3 - INJECTED MICE TREATED WITH LEVAMISOLE - 200 11G/mousE 
GROUP 4 - INJECTED MICE TREATED WITH CORYNEBACTERIUM PARVUM - 300 PG/MOUSE 
GROUP 5 	INJECTED MICE TREATED WITH UNBLOCKED LYMPHOCYTES - 4)(106 CELLS/MOUSE 
GROUP 6 - INJECTED MICE TREATED WITH COMBINATION OF TREATMENTS 3,4 & 5 
MICE RECEIVED AT 5 WEEKS OF AGE - INJECTION OF H238 CELLS AT 12 WEEKS OF AGE 
were washed hourly for 4 hours using RPM-1640 medium. After the 
fourth washing the cells were resuspended and refrigerated overnight 
in RPMI-1640 medium supplemented with 0.2% normal mouse serum. Before 
use the cells were washed 3 times and resuspended in TBS at a con-
centration of 20 x 10
6 
cells/m9.. A combination of treatments applied 
to groups 3, 4, and 5 was administered i.p. to all group 6 mice. 
Four mice from each group (24 total mice) were injected with 
tumor cells or saline (negative controls) and started on a specific 
therapy once a week which continued for seven weeks. All groups 
injected with tumor cells in any one week were considered a panel. 
Treatment for each group within a given panel proceeded on a weekly 
basis for a total of seven consecutive weeks before sacrifice as 
indicated by Table 1. 
Labeling H238 Target Cells  
Cells were split 24 hours prior to labeling and cultured in 
50% Dulbecco's complete medium and 50% RPMI - 1640 complete medium 
(1/2-1/2 medium). The morning the cells were to be labeled they were 
trypsinized from the flasks and taken up in fresh 1/2-1/2 medium. The 
cells were then counted in a hemacytometer and adjusted to a final 
concentration of 1.6 x 106 cells/m2 in 'conditioned' medium, the 
actual growth medium used to culture the target cells 24 hours 
prior to trypsinization. 
Four mks of this cell suspension was added to 4 mk of labeled 
medium. The latter was preapred by combining 0.42mk of 10-4 
17 
18 
fluorodeoxyuridine (FUdR) in RPMI -1640 medium, 3.36 mk conditioned 
medium and 0.48 m2.
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of 	IUdR (final concentration 3 pCi per mk). 
Two mk, of the combined cell suspension and labeled medium was 
pipetted into each of 4 small tissue culture flasks and incubated 
in a 5% CO„ incubator at 37
0 
C for 4 hours. After this period the 
labeled medium was removed and the cells were gently washed 3 times 
in the flasks with conditioned medium. Cells were then trypsinized, 
resuspended in 2 mk conditioned medium, counted in a hemacytometer •and 
adjusted to a concentration of 6.5 x 10
5 
cells/m2 using 1/2-1/2 medium. 
Effector Cells  
Spleens were removed from all test and control animals, weighed, 
and then placed in 3 m9 RPMI - 1640 medium. The spleens were then 
teased with wooden applicator sticks until all cells were released. 
The suspensions were centrifuged and the supernate discarded. 
ACK lysing buffer was added to remove red blood cells. The tubes 
were centrifuged again and the supernate discarded. The remaining 
cells were resuspended in RPMI - 1640 medium, counted in a hema-
cytometer and adjusted to a final concentration of 2.5 x •10
7 
cell/mk, 
using 0.2% trypan blue as an indicator of cell viability. 
Target Cell Incubation - CTT  
1. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) 
Labeled H238 target cells adjusted to a concentration of 6.5 x 05 
cells/m2, were added in 0.1 mk aliquots to 1.2 mk of each test 
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mouse serum sample (groups 2 - 6 mice) obtained that day via cardiac 
puncture (sera were all diluted 1:4 before cells were added to provide 
sufficient volume for test procedures). Target cells were also added 
in the same manner to a 1.2 mk sample of negative control mouse 
serum (group 1 mice) harvested that day. These cell suspensions 
were then mixed and dispensed in 0.1 mk aliquots (5 x 103 cells/ 
well) to each of three microculture plate (Costar, Cambridge, Mass.) 
wells for every test and control animal being assayed for ADCC that 
day. Cells were incubated for 11/2 hours in an atmosphere of 5% CO2  
in air at 37°  C. 
2. Blocking Factor (BF) 
Labeled target cells adjusted to a final concentration of 
6.5 x10
5 
cells/mk Wereadded in 0.1 mk aliquote to 1.2 mk of each 
test mouse serum sample harvested that day. Target cells were also 
dispensed into 1.2 mk samples of negative control sera. Target cells 
suspended in test sera were dispensed in 0.1 mk aliquote (5 x 103  
cells/well) to each of three wells for every test animal. Target 
cells suspended in the negative control sera iwere also dispensed 
into three wells for every test animal assayed that day. The cells 
were incubated for 11/2 hours in a 5% CO2 environment at 37 C. 
3. Cytolytic T-Lymphocytes (CTL) 
Labeled target cells adjusted to a concentration of 6.5 x 105  
cells/m9 were added in 0.1 mk aliquots for every 1.2 mk RPMI - 1640 
medium. One-tenth mk aliquots of this cell suspension were dispensed 
into each of three wells (5 x 103 cells/well) for every test and
negative control animal and incubated for 1\ hours in a 5% co
2
environment at 37° C.
4. Non-Specific Lysis (NSL)
Labeled target cells were added in 0.1 mi aliquots into 1.2 mi
RPMI - 1640 medium. One-tenth mi aliquots of this suspension were 
incubated for 1\ hours in a 5% CO
2 
environment at 37° C.
Cytotoxicity Assays 
All plates wer·e turned upside down and drained to remove any 
unattached target cells 1\ hours after the labeled cells were 
originally added. Effector spleen cells (test or negative control) 
adjusted to a conc�ntration of 2.5 x 107 cells/mi were then added
to each well in 0.1 mi aliquots, to produce an effector to target 
ratio of 500: 1. 
Test animal spleen cells were added to wells involved in the 
blocking factor, blocking factor control and cytolytic T-lymphocyte 
assays. Negative control spleen cells were added to wells set-up 
for the antibody-dependent cell-mediated cytotoxidty and ADCC 
control assays along with the CTL (Natural Killer - NK) control 
wells. One-tenth mi RPMI - 1640 medium was added to each of the 
twelve NSL wells. The plates were incubated for a total of 20 hours 
in a 5% CO
2 
incubator at 37° C.
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At the end of this 20 hour period the plates were harvested with 
a Multiple Automatic Sample Harvester (Mash II, Microbiological 
Associated, Inc., Bethesda, Maryland). The fluid contained in the 
plate wells was collected into one set of tubes (supernate tubes) 
and the 
125
1 released during the incubation period was counted in 
a gamma counter. Unattached who 1 e ce 11 s were collected on fi 1 ter 
.paper discs and added to the second set of tubes. The cells con­
taining unreleased isotope were collected into a second set of tubes 
after washing with sodium dodecyl sulfate (Sigma Chemical Co., St. 
Louis, Mo.) the filter paper discs were added and the tubes were 
counted in a gamma counter. These results plus the supernate tube 
results provided total counts per minute (cpm). The results of the 
release were expressed using an average of the three wells set-up 
for each test and negative control animal for the three cyto-
toxic ity as says. 
NSL Results -
ADCC Results -
Total % NSL = NSL cpm supernate 
x lOO% NSL tota 1 cpm 
ADCC control cpm supernate 
x lOO% = xADCC control total CPM 
ADCC test cpm supernate 
x lOO%; yADCC test tota 1 cpm 0 
Total % ADCC = (Y-X - (X - NSL) 
X - NSL 
X 1QQ% 
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BF Results - 
BF control cpm supernate  
)‹ 100% = X BF control total cpm 
BF test cpm supernate  
x 100% _ - Y BF test total cpm 
Total % BF = (X - NSL) 	(Y - NSL)  
(X - NSL) 
CTL Results - 
CTL control (NK) cpm supernate x 100% = V 
CTL control (NK) total cpm 
(V - NSL)  
x 100% = W (100 - NSL) 
CTL test cpm supernate x 100% = X 
CTL test total cpm 
100% = Y 
Net % CTL = (Y - W) = net % lysis 
Lymphocyte Transformation Test- LTT  
The same spleen cells- (effector cells) obtained and prepared for 
the cytotoxicity tests were used in the LTT assay.- The cells were 
tested for viability by trypan blue exclusion. The cells were then 
counted in a hemacytameter and the concentration adjusted to 1 x 106  
cells/mi. From these spleen cell suspensions, 0.1 mk aliquots were 
dispensed into microculture plate wells. Six wells were set-up for 
every test animal and control animal. Phytohemagglutinin (PHA-P 
Wellcome Research Laboratories, Beckenham, England) adjusted to a 
dillution of 1:60 (determined by prior assay) was dispensed into three 
22 
Total % CTLL= (X - NSL) 
(100 - NSL) 
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of six wells set up for every :animal. Complete RPMI - 1640 medium 
was dispensed into the remaining three wells set-up for each animal. 
The plates were incubated for 43 hours in a 5% CO2 environment at 
37
0 
C. At the end of this period tritiated thymidine was added to each 
well at a concentration of 1 pCi/0.05 mk. The plates were then incubated 
for an additional 5 hours. The cells were harvested using a Mash II 
harvester on glass fiber filters (Whatman, Inc., Clinton, New Jersey). 
The fiber filters were then placed into counting vials containing 2 mk 
counting fluid, Cytoscint (Westchem Enterprises, Inc., San Diego, 
California). An LS - 250 liquid scintillation counter (Beckman 
Instruments, Los Angeles, California) was used to count the 
3
H - thy-
midine incorporated into the DNA of the spleen cells. The results 
obtained from the six - wells (three test wells and three control wells) 
set up for every test and control animal wereaveraged. 
Stimulation Index - S.I.  
The stimulation index indicates the ability of PHA to stimulate 
incorporation of 
3
H - thymidine by test and negative control spleen 
cells. Results were calculated as follows: 
S.I. = 	mean cpm test wells - mean cpm control wells 
with PHA 	without PHA 
mean cpm control wells 
without PHA 
Relative Spleen Weight - R.S.W.  
All test and control animals wereweighed prior to sacrifice. 
The spleens were •removed immediately and weighed. The R.S.W. for 
each mouse was calculated as follows� 
R.S.W. =
Tumor Volume 
spleen weight in mg 
mouse weight in gm/10 
Vernier calipers were used to make weekly measurements of 
progressive H238 tumors. The results were calculated as follows: 
H1 =·height of leg at time-of H238 cell injection
H2 = height of leg with tumor at time of measurement
W = width of tumor 
L = length of tumor 
Statistical Analysis 
Tumor Volume = (H2 - H1
) x W x L
2 
The mean and standard error were calculated for all measurements 
taken. These were used to cafrulate the probability of significance 
using the 2-ta il ed Student I s 11t II test. 
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Results 
Cytotoxicity Assay Re�ults 
1. Anti body-Dependent Cell-Mediated Cytotoxi city
Results obtained for the antibody-dependent cell-mediated
cytotoxicity (ADCC) assay are summarized in Table II and Figure 2. In 
all treatment groups except group 4 the progressive tumor mice had 
lower levels .of ADCC activity than the no visible tumor (NVT) and re­
gressor mice of that same group. Group 6 animals showed the highest 
level, or the least depression from the Oline, of ADCC activity for 
progressor mice. Groups 4 and.5 showed sliahtly lower levels of act�­
vi ty. Interestingly, group 2 mice receiving no . tumor ·therapy had ;a 
sliahtly higher level of ADCC activity than did group 3 progressor mice 
receiving a weekly treatment of levamisole. Note, however, that the 
pertent ADCC was much higher for group 3 NVT and regressor mice. A sig­
nificant difference in response was found between group 3 and group 6 
progressor mice (See Table III for p values). 
2. Blocking Factor
Table II and Figure 3 summarize the cytotoxicity results obtained
in the blockina factor (BF) assays. Untreated progressive tumor mice 
(qroup 2) showed hiaher levels of BF than did any other group of 
treated progressive tumor mice. Group 4 animals possessed the lowest 
or most deoressed levels of percent BF values found in progressors. 
Group 3 progressor mice showed a somewhat higher BF level; however, 
the NVT and rearessor mice in this group possessed the lowest percent 
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TABLE II, CYTOTOX I C I TY RESULTS 
GROUP 2 





Progressorsd  Regressors e  
& NVT f 
Progressord Regre5sorse 
& NVIT 
-120.0±15.8 -87.4±22.8 10.3±30.6 10.4±37.5 -3.4±1.9 0.1±2.5 
GROUP 3 -125.9±5.3 -56.5±31.8 7.5±12.3 -41.6±10.7 -1.3±1.8 -0.5±1.5 
GROUP 4 -102.9±13.4 -104.9±4.6 -14.2±15.4 25.7±29.4 -2.2±1.1 -3.9±1.2 
GROUP 5 -100.6±15.0 -59.0±19.0 -11.2±12.9 10.5±23.6 -1.0±1.7 -0.5±2.7 
GROUP 6 -87.7±15.8 -47.5±15.0 -2.8±9.6 -21.3±9.6 3.0±3.6 -0.2±1.6 
aPercent Antibody Dependent Cell Mediated Cytotoxicity 
bPercent Blocking Factor 
cPercent Cytolytic T Lymphocytes 
dProgressors - mice with progressive tumors at the time of sacrifice 
e
Regressors - mice with tumors that completely regressed before sacrifice 
fNo Visible Tumors - mice with no visible tumors any time during the experiment 
GROUP 3 	GROUP 11 GROUP 5 	 GROUP 6 GROUP 2 
















±19 . 0 
±15 . 8 
111 PROGRESSORS 
Ed NO VISIBLE TUMORS 
& REGRESSORS 
±22 . 8 
15.8 
±19. 0  
±15.0  
±5 . 3 
±31 . 8 
±13.4 ±4.6 
TABLE III. 
	P values obtained for Tumor Volume, Relative Spleen Weight, Stimulation Index, 
Blocking Factor, Cytolytic 1-Lymphocytes and Antibody-Dependent Cell-Mediated 
















1 	vs. 	2 -- 0.001 0.05 
1 	v... 	3 -- 0.001 0.1 
1 	vs. 	4 ' -- 0.001 0.05 
1 	vs. 	5 -- 0.001 0.01 
1 	vs. 	6 -- 0.001 0.05 
2 vs. 	3 -- 0.1 
2 vs. 	4 -- 
2 vs. 	5 -- 0.1 0.05 
2 vs. 	6 -- 0.1 0.1 
3 vs. 	4 -- ' , 0.05r 
3 vs. 	5 __ 0.05r 0.05r 
3 vs. 	6 -- 0.1r 0.05 
4 vs. 	5 0.1 0.05 
4 vs. 	6 0.1 0.1r 0.1T 
5 vs. 	6 0.1 
a Relative Spleen Weight at Sacrifice 
Stimulation Index of Spleen Cells 
Percent Antibody Dependent Cell Mediated Cytotoxicity 
Percent Blocking Factor 
Percent Cytolytic T Lymphocyte - Direct cytolysis 


















GROUP 2 GROUP 3 









BF level of any group tested. As indicated in Figure 3, NVT and 
regre�sor mice in groups 2, 4 and 5 were found to have higher levels 
of blocking factor than did the progressive tumor mice in those same 
groups. Significant p values for this assay are listed in Table III. 
3. Direct Cytolysis - (Cytolytic T-Lymphocytes)
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Results obtained for the cytolytic T-lymphocyte (CTL) assays_are
summat'12ed in Table II and Figure 4. All NVT and regressor mice 
other··than those found in group 4, which showed the greatest suppres­
sion of'_CTL activity, showed hiqher direct cytolysis results than did. 
the progressive tumor mice of the same group.· In comparing the pro­
gressor mice, those in untreated group 2 showed the most suppression 
of target cell lysis due to cytolytic T-lymphocytes. Results for 
combination therapy group 6 progressor mice showed the most elevated, 
or least depressed CTL results. Groups 3 and 5 progressor mice had 
somewhat lower CTL activities. Group 4 progressors showed an even 
lower-�TL response to target tumor cells than groups 3 and 5. No 
significant p values were obtained for this particular assay. 
Lymphocyte Transformation Test Results 
1. Stimulation Index (S.I.) - Spleen Cells
Mean stimulation index results obtained from the lymphocyte
transformation test are summarized in Table IV and Figure 5. In all 
groups the NVT and regressor mice had obviously higher.mean S.I. 



























GROUP 2 GROUP 3 GROUP 4 
FIGURE 4. CYTOLYTIC T-LYMPHOCYTE RESULTS 
±3.6 
GROUP 5 GROUP 6 
TABLE IV. 	STIMULATION INDEX RESULTS 
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5 GROUP 6 
aPROGRESSORS ___ 4.2±0,9 3,0±0.6 410±0.7 2,2±0.4 2.1.-±0.4 
bREGRESSORS & 
cNVT MICE 








aProgressors - mice with progressive tumors at the time of sacrifice 
bRegressors - mice with tumors that completely regressed before sacrifice 
cNo Visible Tumors - mice with no visible tumors any time during experiment 
dNegative Controls - non-injected mice injected only with saline) 
±0.4 
GROUP 4 GROUP 5 	GROUP 6 GROUP i 	GROUP 2 	GROUP 3 
EJ PROGRESSORS 

































FIGURE 5. 	LYMPHOCYTE TRANSFORMATION TEST RESULTS 
±1.0 
-±1.4 
Phytohemagglutinin (PHA) stimulated the spleen cells of the non­
injected negative control mice in group 1 to a greater extent than 
any other group of mice eicept for the NVT and regressor mice in 
group 4. A significant difference was found between the group 1 
mean S.I. value and those found for all other test groups. Group 
2 progressors al though not treated with any anti-tumor therapy had 
a slightly higher mean S.I. than did any other group of progressive 
tumor mice. The mean S.I. found for group 2 progressors was sig­
nificantly higher than those found for group 5 and 6 progressors . 
. However, group 2 NVT and regressor mice did not show a significantly 
higher S. I. than any other group of NVT and regressor mice._ Group 
4 progressors treated only with�. patvum had a significantly higher 
mean S.I. than did group 5 or 6 progressive tumor mice. The NVT and 
regressor mice in this group showed a significantly higher S.I. value 
than did group 5 and 6 NVT and regressors. Group 3 NVT and regressors 
also had significantly highe�mean S.I. values than did groups 5 and 
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6 NVT and regressors. However, group 3 progressors were found to have 
a lower S.I. value than progressors in groups 2 and 4, �nd only a 
slightly higher NVT and regressor S.l. than found for groups 5 and 6. 
Combination treatment group 6 progressors had the lowest mean S.I. 
for any group tested. Table III gives the significant p values for 
S.I. results. 
Relative Spleen Weights (R�S.W.) 
Table V and Figure 6 summarize the mean relative spleen weights 
and standard error calculated for each test group of mice at the time 
of sacrifice. Mice with progressive tumors at the time of sacrifice 
were found to have greatly enlarged spleens which is indicated by 
high R.S.W. values. Negative control mice in group 1 had the lowest 
R.S.W. 's for any experimental group. Progressors within group 2 had 
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a lower mean R.S.W. than any other progressive tumor group. Progressors 
in groups 3 and 6 showed the highest R.S.W.'s. Group 4 and 5 progressors 
did not show significantly lower R.S.W.'s. All NVT and regressor mice 
within any given treatment group had much lower R.S.W. 's than did- the 
progressors within that same group. Table III gives the significant 
p values for R.S�W. results. 
Progressive Tumor Measurements 
1. Tumor Volume
Weekly calculations of tumor volume were made for each progressor
animal included in the experiment. Vernier calipers were used to take 
the necessary measurements. The results. obtafned are depicted in 
Figure 7. No visible tumors were found in any of the negative control 
group 1 mice throughout the study. Tumors appeared in groups 2, 3, 4 
and 5 one week after the inejction of l x 10
6 
H238 tu�or cells per 
mouse. Group 6 had the slowest onset of tumor development. In this 
group tumors did not appear until the second· week of therapy. Group 
4 and 6 mice showed the lowest mean tumor volume values at the end of 
a seven w�ek treatment period. Group 5 mice treated with unblocked 
lymphocytes and group 3 mice treated with levamisole showed even 
TABLE V. 	RELATIVE SPLEEN WEIGHTS 
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5 GROUP 6 




--- 44.0±1.6 41.9±1.8 61.6±12.0 46.0±2.4 59.8±5.4 
d 
NEGATIVE CONTROLS 40.2±1.0 ___ ___ ___ ___ ___ 
aProgressors - mice with progressive tumors at the time of sacrifice 
bRegressors - mice with tumors that completely regressed before sacrifice 
c
No Visible Tumors - mice with no visible tumors any time during the experiment 
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FIGURE 7. 	TUMOR VOLUME IN CUBIC MILLIMETERS 
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greater mean tumor volumes at the end of the seven week period than 
did the group 2 mice receiving no tumor therapy. Without exception, 
once tumors began to develop, all groups. showed a weekly increase in 
mean tumor volume. 
2. 	Tumor Incidence 
Table VI and Figure 8 summarize the tumor incidence results 
calculated for all six experimental groups of mice. Progressive 
tumors were found within each group of mice except the non-injected 
control group 1 mice. Groups 4 and 5 showed the highest progressive 
tumor incidence, each at 83.3 percent. Group 2 mice receiving no tumor 
therapy had a 66.7 percent progressor incidence. Mice in treatment groups 
3 and 6 shared the lowest progressor incidence at 61.9 percent. Com-
plete regression of observable tumors occured in only two mice during 
the study. One mouse was in group 4, the other in group 5. One hundred 
percent of the group 1 negative control mice failed to develop 
observable tumors. These were classified as NUT mice. Groups 3 and 6 
each showed 38.1 percent of their population to be NVT mice. Within 
group 2, 33.3 percent were NUT mice. Groups 4 and 5 had a lower NVT 
incidence at only 12.5 percent. 
TABLE VI. INCIDENCE OF PROGRESSORJ REGRESSOR AND NO 
VISIBLE TUMOR MICE 











83.3% 4.2% 12.5% 
GROUP 4 
(20/24) (1/24) (3/24) 
83.3% 4.2% 12.5% 
GROUP 5 





Progressors - mice with progressive tumors at the time of sacrifice 
bRegressors - mice with tumors that complet�ly regressed before sacrifice
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� NO VISIBLE TUMOR 
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5
FIGURE 8. INCIDENCE OF PROGRESSOR J REGRESSOR AND NO VISIBLE TUMOR MICE 
GROUP 6
DISCUSSION  
The dependence of anti-tumor cell cytotoxicity upon antibody 
Production was measured in the ADCC assay. Those mice bearing 
progressive tumors at the time of sacrifice had more suppression 
of ADCC against target cells than did NVT and regressor mice. Group 
6, treated with a combination therapy of levamisole, C. parvum and un-
blocked lymphocytes over a seven week period had the highest, or 
least depressed, level of ADCC activity for any group of progressor 
mice. Group 3 progressors treated weekly only with 200 pqm of leva-
misole showed the lowest percent target cell lysis due to ADCC. NVT 
and regressor mice in this same group, however, had one of the 
highest ADCC activity levels (Figure 2). 
It has been-suggested that the effectiveness of levamisole as 
an anti-tumor chemotherapeutic agent is directly dependent upon the 
initial immune status of the tumor host (Brulet-Rosset, et al., 
1978; Goldstein, 1978; Ameny, 1976) and the dose of levamisole ad-
ministered (Focan, 1979). Therefore, the results obtained may indicate 
that the immune status of the group 3 progressor mice was not initially 
depressed to such an extent that would actually be enhanced by 
levamisole administration. Just as plausible may be a lowered ADCC 
activity due to too high a weekly dosage of levamisole. The 200 pgm 
per mouse dosage was based on Bansal's (1978) work where an i.v. dose 
of 1 mg per rat (equivalent of 5 gm/Kg rat weight) was used. Because 
we were unable to successfully administer the treatments i.v., we 
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compensated by doubling the dosage and administering it i.p. 
Those animals in our study with more active immune systems may 
have been able to compensate for the immunosuppressive effects of 
excessive amounts of levamisole. Group 4 progressor mice treated with 
C. parvum, which non-specifically stimulates macrophanges, and group 
5 progressors treated with unblocked lymphocytes showed higher ADCC 
activity than did the group 3 progressors. C. parvum and unblocked 
lymphocytes may then be the actual therapy combination that caused the 
higher percent ADCC seen in group 6 progressor animals. However, an 
enhanced synergistic effect may have been due •to the combination of 
levamisole, C. parvum and unblocked lymphocytes. 
Serum blocking factors may actually aid tumor cells in escaping 
the host's immune surveillance system. Progressor mice would pre-
sumably possess higher levels of such blocking factors than would 
NUT and regressor mice. In the results for the blocking factor (BF) 
assay (Figure 3), group 2 progressors had a higher level of BF than 
any other group of progressive\-tumor mice. This suggests that 
individual tumor treatments or a combination of treatments may play 
a role in lowering BF levels in a tumor host, thereby possibly 
increasing direct or indirect tumor cell cytolysis by the immune 
system of the host. Progressor mice in group 3 showed a level of 
BF almost as high as the progressors in group 2. NUT and regressor 
mice in group 3 possessed the lowest level of BE for any group of 
mice charted. Results of the 200 ligm of levamisole administered 
alone again indicate an immunosuppressive role possibly related to 
dosage (Sampson, 1977; ·sampson·, et �-, 1977). Group 4 and 5 pro­
gressors showed a -lower BF le�el than did the NVT and regressor 
animals in these same groups. NVT and regressors in group 4 had the 
highest percent BF and the least Percent CTL. Therefore, progres-
stve tumors in these animals may not be due to the anticytolytic 
effect of BF in regard to tumor cells. Group 6 progressor animals 
treated with a combi'natfon therapy of levamisole, f_. parvum and 
unblocked lymphocytes were found to have higher levels of BF in 
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their serum than did either group 4 or 5 progressors. Levamisole 
administered at too high a dosage may have acted as an antagonist and 
minimized the beneficial effects of�- parvum and unblocked lymphocytes 
together. 
The direct cytolytic capabilities of T-lymphocytes is well 
documented (Plata, et _tl., 1976; Hellstrom and Hellstrom, 1969). 
The ability of T-cells to directly lyse H238 target tumor cells is 
recorded in Figure 4. Progressive tumor mice in group 2 had the 
least cytolytic T-lymphocyte (CTL) activity of progressors found in 
any group. The NVT and reqressors found in group 2 however, had a 
higher level of CTL activity than did any of the NVT and regressor 
mice in treatment groups 3, 4, or 5. While the progressors in these 
groups showed less inhibition of direct tumor cell cytolysis � vitro 
than did group 2 progressors, the NVT and regressor mice abilities 
to directly lyse target tumor cells was depressed even with therapy. 
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Surprisingly, the combination of levamisole, C. parvum and unblocked 
lymphocytes stimulated direct cytolysis by T-cells collected from 
the group 6 NUT and regressor animals. The three treatments adminis-
tered together appeared to have a synergistic effect on these mice. 
Group 6 progressors also showed less suppression of CTL activity than 
did any other group of progressive tumor mice. 
The lymphocyte transformation test is used as a general indicator 
of host immune cell responsiveness. The results found in Figure 5 
indicate that spleen cells collected from non-injected mice in neg-
ative control group 1 showed comparatively high stimulation index 
(S.I.) values. Lymphocytes collected from tumor-bearing hosts usually 
are less stimulated by PHA than are cells collected from NUT and re-
gressor mice and from normal, non-injected mice (Gillette and Boone, 
1975; Sample, et al., 1971). Results from group 1 non-injected mice 
followed such a pattern. In group 3, 4, 5 and 6 progressors the S.I. 
was lower than for the group 2 progressors, indicating that all of 
the anti-tumor treatments alone and in combination may have somehow 
affected the responsiveness of the T-cells to PHA. Levamisole ad-
ministered at too high a dosage is immunosuppressive (Sampson, et al., 
1977); while C. parvum is known to non-specifically stimulate macro-
phages, not necessarily T-cells (Ghaffar, et al., 1975; Ghaffar, et 
al., 1974; Wolmack, 1974). Unblocking T-lymphocytes, however, would 
be expected to increase the metabolic activity of the group 5 mice 
(Doyle, 1974). This did not occur in our study. 
In each of these groups the NVT and regr�ssor mice had slightly 
higher S.I. values than did the progressive tumor mice of that same 
group. These results would be expected. Group 4 NVT and regressors 
had a low S.I. value. Combined therapy group 6 progressors had the 
lowest S.I. value for any group tested. This indicated that treat­
ment with the combination of levamisole, �- parvum and unblocked 
lymnhocytes associated with progressive tumor growth depressed the 
T�cell activity level more than when each treatment was used individ­
ually. However, the combination treatment did not significantly 
depress the S.I. level. 
Splenomegaly is often observed in �ice- bearing progressive 
tumors (Nutter,.§!�., 1980; Rowland, et �.,1973). This pre­
sumably occurs because of increases in blood cell formation and 
cell sub-populations of the immune system migrating into the spleen 
of tumor bearing animals. As would be expected, those mice in 
negative control group 1, had the lowest R.S.W.s. Group 2, 3, 4, 
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5 and 6 progressive tumor mice all showed mean R.S.W.s much higher 
than for the NVT and reqressor mice found within those same treatment 
groups. 
Tumors did not develop in any of the negative control group 1 
mice. Tumors were found in group 2, 3, 4 and 5 mice one week after 
injection of 1 x 106 H238 tumor cells into the right hind leg of each
animal. Steady increases in mean tumor volume proceeded for each of 
these test groups until sacrifice. Group 6 progressors did riot show 
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signs of tumor development until two weeks after H238 cell injection. 
The combination of levamisole, C. parvum and unblocked lymphocytes 
would appear to have delayed the development of tumors. In 1966, 
Woodruff reported that C. parvum was able to delay tumor development. 
He also noted that once the tumors were initiated, they progressed just 
as quickly as those in hosts receiving no C. parvum treatment. Two 
of the twenty progressors treated only with C. parvum (group 4) 
developed tumors one week after initial tumor cell injection. It 
appears that the C. parvum may have the ability to delay tumor 
development. 
Only one of the twenty progressors in group 5 treated only 
with unblocked lymphocytes developed a tumor after the first week 
of therapy. After the initial delay in appearance, tumors progres-
sively enlarged on a weekly basis for group 4 and 5 mice just as 
they did for the group 6 progressors. It was expected that group 2 
progressors receiving no anti-tumor therapy would develop the 
largest tumor volumes at the end of the seven week treatment period. 
However, group 5 progressors treated with unblocked lymphocytes had 
the largest mean tumor volume at the time of sacrifice, followed 
closely by group 3 progressors. The results in group 5 may be 
due to the administration of the unblocked lymphocytes i.p. rather 
than i.v. as Bansal's (1978) group did. 
The reason the administration route was changed was because of 
the very small diameter of the mouse tail veins. Attempts to inject 
the unblocked lymphocytes into these veins were made but much of the 
treatment sample was lost during injection. Standardization of cell 
numbers would be very imprecise. It was decided, therefore, to use 
an i.p. administration route. 
·Throughout the seven week therapy period the mean tumor volumes
of these three groups did not differ significantly.· Progressor mice 
treated with£. parvum alone (grouo 4) and in combination with 
levamisole and unblocked lymphocytes (group 6) had the lowest 
48 
mean tumor volume at the end of the study. These tumor volumes did 
differ significantly from those of group 5 (Table II). These results 
indicate that£: parvum played a role in retarding tumor appearance 
and reducing tumor volume. These results coincide with results 
obtained by other i nves ti gators ( Bans a 1 , et .tl.· , 1978; Fis her, et .tl_. , 
1975; Currie and Bagshawe, 1970; Fisher, et .tl.-, 1970; Halpren, 
et �l . , 1966) . 
It was also found that the ADCC and BF test results positively 
correlate with the tumor volume results found for group 4 and 6 mice. 
This again indicates a role for£. parvum in enhancing the overall 
immune status of progressor mice. Although the CTL results for 
progressor mice were the least suppressed in the combination therapy 
group 6 mice, the group 4 mice treated only with£. parvum showed a 
much more depressed level of percent direct cytolysis. This might be 
expected since£. parvum non-specifically stimulates macrophages, and 
this particular test involves the ability of T-lymphocytes to directly 
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lyse target tumor cells. While unblocked lymphocytes may have the 
ability to delay tumor appearance, they seem to have no affect on 
reducing tumor volume. Levamisole showed no apparent affect upon 
tumor appearance or progression. 
As would be expected, no visible tumors were found in any of 
the negative control group 1 mice. Progressive tumors developed in 
83.3 percent of the mice in groups 4 and 5. These were the only 
two groups however, where complete regressors were found (one in 
each group, but 33.3 percent of the mice never developed tumors. 
Injections of 1 x 10
6 
H238 cells per mouse were expected to cause 
tumors in essentially 100 percent of the positive control mice 
(Boyd and Orme, 1975). 
Another TD
50  study would have to be performed before using 
H238 cells again to determine at what cell concentration 100 percent 
of the mice used would develop progressive tumors. With respect to the 
results of the immune status testing, it was surprising that group 3 
animals treated only with levamisole shared the lowest incidence of 
tumor progression with those mice in group 6 (62.0 percent). In 
Bansal's (1978) study of a rat tumor model, 1, 2-dimethylhydrazine 
was used to initiate colon tumors. Treatment with a combination of 
levamisole, C. parvum and unblocked lymphocytes resulted in 60.0 
percent progressor mice, 20.0 percent regressor mice and 20.0 
percent NVT mice. Our study employed the use of Balb/c H238, 
HSV-2 transformed cells and we measured only the effects upon tumor 
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promotion. Therefore, our slightly higher progressor tumor incidence 
for combination therapy group 6 mice should not be surprising as 
initiation of the tumor cells had already taken place before injection 
into the test animals. Our NVT incidence was actually higher than that 
recorded for Bansal's combination therapy group. However, we recorded 
no regressors in comparison with his 20.0 percent figure. The group 6 
animals developed tumors at the slowest rate and showed a lower mean 
tumor volume than the group 3 animals. 
Interestingly, our results correlate favorably with the ADCC and 
CTL cytotoxicity results found for the group 6 progressors. This tends 
to indicate that the combination of C. parvum with levamisole and un-
blocked lymphocytes does have an enhancing effect upon the immune 
status of tumor, hosts, which may aid in lowering tumor incidence and 
reducing tumor volume. 
Conclusions 
Some types of chemotherapeutic immunostimulation appear to be 
able to increase specific activitie�_of a tumor host 1 s .immune�system�­
However, because in vitro testing indicates that a particular anti­
tumor therapy partially restores the normal immune response of a 
host animal, this does not mean that all or any foreign tumor cells 
will acutally be destroyed. 
This particular study indicated tha levamisole administered at 
the dosage of 200 µgm per mouse had no stimulatory affect upon the 
host's immune system. It may have acted in some fashi.on to reduce 
the overall tumor incidence of group 3 mice (although no significant 
difference was found between group 3 and any other test group of mice 
including group 2 untreated mice). However, this study did not include 
any inmunological measurements that would explain this lower tumor 
incidence. 
f. parvum used as an irrmunostimulator was somewhat effective in
decreasing the suppression of ADCC activity in comparison with group 
2 mice. The BF level appeared to be lower than that found for pro­
gressors in the positive control group also. Mean tumor volume was 
significantly reduced in group 4 progressors and tumor appearance was 
delayed in comparison with group 2 and 3 mice. Therefo_re, f. parvum 
does have a potential role in tumor therapy. 
Group 5 mice treated only with unblocked lymphocytes showed 
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slight increases in ADCC and CTL activity along with a lower level 
of BE activity than those mice in group 2. However, the mean tumor 
volume for this group was even higher than for the positive controls. 
Also, tumor incidence was the highest in this group of mice. It does 
not appear from this study that unblocked lymphocytes administered 
alone have a significant role in tumor therapy. 
Combining the three chemotherapeutic agents appeared to increase 
the overall immune responsiveness of the test animals as indicated by 
the ADCC and CTL results. Although this immune stimulation may well 
be responsible for the lower tumor incidence and the lower mean tumor 
volume found for this study group, the treatments used in combination 
would have to be further divided and studied in order to definitely 
determine which of the three therapeutic agents or combination of 
agents were the most stimulatory. The combination administered to 
group 6 animals did play .a role in delaying the appearance of pro-
gressive tumors and reducing tumor incidence. 
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